We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Similarly, Celgene’s blood cancer drug Imnovid/Pomalyst (pomalidomide) saw sales of $513 million in the third quarter, a 23 percent year-over-year increase, and its non-small cell lung cancer treatment Abraxane (paclitaxel) saw revenues increase by 15 percent year-over-year to $288 million. Read More
Bristol-Myers Squibb’s planned acquisition of Celgene this year will dramatically increase BMS’ position in oncology drugs as it absorbs the New Jersey-based company’s portfolio of existing cancer drugs and promising pipeline products. Read More
Drug companies’ returns on R&D investments have sunk to their lowest level since 2010 and analysts at Deloitte attribute the decline mostly to the soaring costs of clinical trials. Read More
The state’s supreme court affirmed that the sudden downturn in Akorn’s generic drug business — before the deal was final — justified Fresenius’ reversal. Read More
A month after a scathing congressional report hit Kaléo for hiking prices for its opioid antidote by 600 percent, the company announced it will release a lower-cost generic version of its auto-injector in 2019. Read More
Three former Genentech employees were indicted by a federal grand jury for allegedly stealing trade secrets from the San Francisco-based Roche subsidiary, which is pursuing litigation of its own against the ex-staffers. Read More